TPMT与NUDT15基因分型对儿童炎症性肠病硫唑嘌呤或6-巯嘌呤治疗耐受性的干预效果分析
该回顾性队列研究纳入181例计划使用硫唑嘌呤或6-巯嘌呤的炎症性肠病患儿,其中13例因基因变异未用药。接受治疗的168例中,基因型检测组77例,未检测组91例;未检测组总不良反应比例(40.7% vs. 26.0%,P<0.05)及胃肠道反应发生率(24.2% vs. 3.3%,P<0.01)均显著更高。用药前TPMT及NUDT15基因分型有助于指导药物选择并减少不良反应。
要点
- 用药前TPMT及NUDT15基因分型可指导硫唑嘌呤或6-巯嘌呤的临床药物选择。
- 基因型未检测组总不良反应比例40.7%,显著高于检测组的26.0%(P<0.05)。
- 基因型未检测组胃肠道反应发生率24.2%,显著高于检测组的3.3%(P<0.01)。
核心结论
- 用药前TPMT及NUDT15常见基因型检测有助于指导临床药物选择,减少整体药物不良反应发生率,增加患儿对硫唑嘌呤或6-巯嘌呤治疗的耐受性。
研究设计与样本
- 回顾性队列研究纳入2010年1月至2023年1月浙江大学医学院附属儿童医院消化内科计划使用硫唑嘌呤或6-巯嘌呤的IBD患儿181例。
- 181例中13例因用药前基因检测存在变异未选择硫唑嘌呤或6-巯嘌呤,余168例接受治疗并分为基因型检测组77例与未检测组91例。
主要发现
- 168例接受治疗患儿中克罗恩病154例、溃疡性结肠炎14例;男108例、女60例。
- 药物相关不良反应包括骨髓抑制26例(15.5%)、肝功能损伤18例(10.7%)、胃肠道反应25例(14.9%)、脱发12例(7.1%)、发热3例(1.8%)、皮疹2例(1.2%)、胰腺炎1例(0.6%)。
- 基因型未检测组总不良反应比例40.7%(37/91)明显高于基因型检测组26.0%(20/77)(P<0.05)。
- 基因型未检测组胃肠道反应发生率24.2%(22/91)明显高于基因型检测组3.3%(3/77)(P<0.01)。
- Cox回归分析显示用药前未检测基因型出现因不良反应停药的风险比(HR)为1.47(95%CI 0.65~3.30)。
关键数值与推荐
- 总不良反应比例:基因型未检测组40.7%(37/91) vs. 基因型检测组26.0%(20/77),P<0.05。
- 胃肠道反应发生率:基因型未检测组24.2%(22/91) vs. 基因型检测组3.3%(3/77),P<0.01。
- 因不良反应停药风险比:基因型未检测组HR=1.47(95%CI 0.65~3.30)。
临床怎么用
- 对计划使用硫唑嘌呤或6-巯嘌呤的IBD患儿,用药前应进行TPMT及NUDT15常见基因型检测以指导药物选择。
- 基因型检测有助于降低整体药物不良反应及胃肠道反应发生率,提高治疗耐受性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the impact of pre-treatment TPMT and NUDT15 genotyping on medication selection, tolerability and discontinuation rates of azathioprine or 6-mercaptopurine therapy in children with inflammatory bowel disease (IBD). Methods: A retrospective cohort study was conducted on 181 children with IBD who were scheduled for azathioprine or 6-mercaptopurine therapy at the Department of Gastroenterology, Children's Hospital, Zhejiang University School of Medicine between January 2010 and January 2023. Among them, 168 children who received treatment were divided into a genotyped group and non-genotyped group based on pre-treatment TPMT and NUDT15 genotyping. The incidence of drug-related adverse reactions was compared between the two groups. The impact of genotyping on medication selection and discontinuation rates was analyzed. Chi-square test or Fisher exact test were used for intergroup comparisons. Logistic regression analysis was used to control the confounding factors. Firth Logistic regression analysis was applied for data with complete separation. The probability of discontinuation was assessed using survival analysis with Cox proportional hazards modeling. Results: Among the 181 children with IBD, 13 did not receive azathioprine or 6-mercaptopurine due to genetic variants, while the remaining 168 underwent the therapy (154 cases of Crohn's disease and 14 cases ulcerative colitis; 108 males and 60 females). Excluding the 13 untreated cases, 77 children underwent TPMT and NUDT15 genotyping were assigned to the genotyped group, and the remaining 91 to the non-genotyped group. Adverse reactions included myelosupression (26 cases,15.5%), hepatotoxicity (18 cases,10.7%), gastrointestinal disturbance (25 cases,14.9%), alopecia (12 cases,7.1%), fever (3 cases,1.8%), rash (2 cases,1.2%), and pancreatitis (1 case,0.6%). The incidence of overall adverse reactions was significantly higher in the non-genotyped group compared to that of the genotyped group (40.7% (37/91) vs. 26.0% (20/77), P<0.05). Specifically, the non-genotyped group had a higher rate of gastrointestinal reactions compared to the genotyped group (24.2% (22/91) vs. 3.3% (3/77), P<0.01). Cox regression analysis revealed that non-genotyped group had a higher risk of treatment discontinuation due to the adverse reactions (HR=1.47, 95%CI 0.65-3.30). Conclusion: Pre-treatment genotyping of TPMT and NUDT15 variants can help guide the selection of clinical drugs, reduce the incidence of drug-related adverse reactions and enhance tolerability of azathioprine or 6-mercaptopurine therapy in IBD children. 目的: 观察用药前TPMT及NUDT15常见基因型检测对硫唑嘌呤或6巯嘌呤治疗儿童炎症性肠病(IBD)耐受性、临床药物选择及停药率的影响。 方法: 回顾性队列研究。以2010年1月至2023年1月浙江大学医学院附属儿童医院消化内科就诊并计划使用硫唑嘌呤或6巯嘌呤治疗的IBD患儿181例为研究对象,根据用药前是否进行TPMT、NUDT15常见基因型检测,将接受药物治疗的168例患儿分为基因型检测组及基因型未检测组,比较两组患儿药物相关不良反应发生率。分析用药前基因检测对临床药物选择及停药率的影响。组间比较采用χ2检验或Fisher确切概率法。混杂因素的控制采用Logistic回归分析。完全分离数据采用Firth Logistic回归分析。采用Cox风险比例模型分析两组停药风险比。 结果: 181例IBD患儿中13例患儿因用药前基因检测存在变异而未选择硫唑嘌呤或6巯嘌呤治疗,余168例患儿接受了上述药物治疗,其中克罗恩病154例,溃疡性结肠炎14例;男108例、女60例。90例患儿在用药前进行了NUDT15及TPMT基因型检测,除去13例未用药者,77例归入基因型检测组,余91例归入基因型未检测组。药物相关不良反应包括骨髓抑制(26例,15.5%)、肝功能损伤(18例,10.7%)、胃肠道反应(25例,14.9%)、脱发(12例,7.1%)、发热(3例,1.8%)、皮疹(2例,1.2%)、胰腺炎(1例,0.6%)等。基因型未检测组出现总不良反应患儿比例(37例,40.7%)明显高于基因型检测组(20例,26.0%)(P<0.05)。基因型未检测组胃肠道反应的发生率明显高于基因型检测组[24.2%(22/91)比3.3%(3/77),P<0.01]。经Cox回归分析,用药前未检测基因型出现因不良反应停药的风险比(HR)为1.47(95%CI 0.65~3.30)。 结论: 硫唑嘌呤或6巯嘌呤治疗前行TPMT及NUDT15常见基因型检测有助于指导临床药物的选择,减少整体药物不良反应的发生率,增加患儿对整体治疗的耐受性。.
引用
- Luo YY, Cheng Q, Fang YH, et al. [Intervention effect analysis of TPMT and NUDT15 genotyping on the tolerability of azathioprine or 6-mercaptopurine therapy in pediatric inflammatory bowel disease]. Zhonghua Er Ke Za Zhi. 2025. PMID: 40393756. doi:10.3760/cma.j.cn112140-20250415-00338
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。